Linked from

The 15 pages that link to Minimal residual disease, each with the reason it gives.

• BiomarkerRelated: Biomarkers can reveal residual cancer before it becomes detectable by conventional methods.

• Flow cytometryRelated: Multicolor assays can detect abnormal cells among abundant normal blood cells.

• LymphomaRelated: Sensitive detection may help estimate relapse risk in selected lymphoma types.

• LeukemiaRelated: Residual leukemia cells can persist despite apparent remission and contribute to relapse.

• Multiple myelomaRelated: Sensitive marrow testing can assess how completely myeloma therapy has suppressed the disease.

• Acute myeloid leukemiaRelated: Sensitive tests for residual AML can help estimate relapse risk after remission.

• Myelodysplastic syndromeRelated: Its measurement may help assess response and relapse risk after MDS treatment.

• Acute lymphoblastic leukemiaRelated: Its measurement after therapy helps estimate relapse risk in ALL.

• Clonal evolutionRelated: Surviving clones can seed relapse after an apparent response.

• RelapseRelated: Residual cancer cells can survive apparent remission and later drive relapse.

• Liquid biopsyRelated: Serial tumor-DNA testing can seek residual disease that imaging cannot yet reveal.

• OncologyRelated: Measuring it may reveal relapse risk and help tailor follow-up therapy.

• Adjuvant therapyRelated: Detecting it could identify who still needs adjuvant treatment.

• Molecular pathologyRelated: Molecular assays can monitor residual cancer below routine detection thresholds.

• Circulating tumor cellsRelated: Blood-based cell detection may contribute to assessing persistent disease, though sensitivity is limited.